Page 4 - நிறுவனம் க்கு ப்ரோடீந் வடிவமைப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Seattle s HDT Bio to start U S clinical trials of its COVID-19 vaccine candidate
geekwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from geekwire.com Daily Mail and Mail on Sunday newspapers.
Artificial Proteins Never Seen in the Natural World Are Becoming New COVID Vaccines and Medicines
scientificamerican.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from scientificamerican.com Daily Mail and Mail on Sunday newspapers.
Icosavax Appoints Thomas J Russo Chief Financial Officer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
SK bioscience secures CEPI funds for Phase III Covid-19 vaccine trial 25 May 2021 (Last Updated May 25th, 2021 12:26)
SK bioscience to receive up to $173.4m from CEPI to support the Phase III trial of its Covid-19 vaccine candidate, GBP510.
Share Article
In this ultrapotent Covid-19 vaccine candidate, 60 coronavirus protein pieces are arrayed on a nanoparticle. Credit: Ian Haydon/Institute for Protein Design.
South Korea-based SK bioscience is set to receive up to $173.4m (KRW200bn) in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to support the Phase III trial of its Covid-19 vaccine candidate, GBP510.
The funds will also be used for other development work related to the vaccine, including regulatory activities, commercial processes development, buying raw materials and research and development on response to variants.